newsfilter
← Latest News
GlobeNewswire·

Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

-- Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with obesity due to a heterozygous variant of the